Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321450 | 0.92 | EPHX2 (0.77) | EPHX2ALDH1A1 | |
| SCHEMBL25088985 | 0.85 | EPHX2 (0.69) | EPHX2ALDH1A1 | |
| SCHEMBL19966024 | 0.80 | EPHX2 (0.77) | EPHX2ALDH1A1 | |
| SCHEMBL4611077 | 0.80 | LMNA (0.59) | EPHX2ALDH1A1LMNA | |
| SCHEMBL12931878 | 0.79 | EPHX2 (1.00) | EPHX2ALDH1A1 | |
| SCHEMBL1678218 | 0.79 | ALDH1A1 (0.70) | EPHX2ALDH1A1 | |
| SCHEMBL6160876 | 0.77 | ALDH1A1 (0.50) | EPHX2ALDH1A1LMNA | |
| SCHEMBL19509238 | 0.77 | EPHX2 (0.81) | EPHX2ALDH1A1 | |
| SCHEMBL15189250 | 0.77 | MEN1 (0.51) | EPHX2ALDH1A1LMNA | |
| SCHEMBL16158150 | 0.76 | ALDH1A1 (0.70) | EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457205-A1 | ANGIOGENESIS INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | EPHX2 2354/4885ALDH1A1 1014/4885LMNA 4863/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | EPHX2 2296/4885ALDH1A1 1011/4885LMNA 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.